LCL161 + paclitaxel

LCL161 + paclitaxel is an investigational combination therapy consisting of the small molecule inhibitor of apoptosis protein (IAP) antagonist LCL161 and the chemotherapeutic agent paclitaxel. - **LCL161** is a Smac mimetic that targets and degrades cellular IAPs (cIAP1 and cIAP2), leading to activation of caspase-8 and caspase-3, thereby promoting apoptosis in cancer cells. It has been shown to sensitize tumor cells to chemotherapy by overcoming resistance mechanisms related to IAP overexpression[2]. - **Paclitaxel** is a microtubule-stabilizing agent that inhibits cell division by binding β-tubulin, preventing microtubule depolymerization, resulting in mitotic arrest and apoptosis[6][8]. The combination has been studied in advanced solid tumors including triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). In clinical trials for TNBC with GS-positive status, the combination improved pathologic complete response rates compared to paclitaxel alone[1][4][5][9]. Preclinical studies also show enhanced antitumor activity versus either drug alone due to synergistic induction of apoptosis via complementary mechanisms[2].

Other names

paclitaxel + LCL161